FMP
NASDAQ
2.61 USD
0.005 (0.192%)
Mr. Michael J. McElhaugh
Healthcare
Biotechnology
https://www.arbutusbio.com
NASDAQ
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destab...
0001447028
CA03879J1003
03879J100
701 Veterans Circle
267 469 0914
US
73
Jul 26, 2007
0001447028
NASDAQ
Biotechnology
Healthcare
03879J100
CA03879J1003
US
2.6
2.04
961.67k
467.58M
-
1.69-3.15
-2.13
-
-
-
-
-5.92
-
https://www.arbutusbio.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.